CYCS, cytochrome c, somatic, 54205

N. diseases: 67; N. variants: 4
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
Posterior Circulation Transient Ischemic Attack
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
Carotid Circulation Transient Ischemic Attack
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
Transient Ischemic Attack, Vertebrobasilar Circulation
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
Crescendo Transient Ischemic Attacks
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
CUI: C0751022
Disease: Brain Stem Ischemia, Transient
Brain Stem Ischemia, Transient
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
CUI: C0917805
Disease: Transient Cerebral Ischemia
Transient Cerebral Ischemia
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
Transient Ischemic Attack, Anterior Circulation
0.300 Biomarker disease CTD_human Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice. 11333366 2001
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.300 Biomarker disease CTD_human Mitochondrial adaptations to obesity-related oxidant stress. 10860543 2000
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis
0.300 Biomarker disease CTD_human Mitochondrial adaptations to obesity-related oxidant stress. 10860543 2000
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 GeneticVariation disease GWASCAT Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. 23535033 2014
CUI: C0002395
Disease: Alzheimer's Disease
Alzheimer's Disease
0.100 GeneticVariation disease GWASDB Genome-wide association study of the rate of cognitive decline in Alzheimer's disease. 23535033 2014
CUI: C0008479
Disease: Chondrosarcoma
Chondrosarcoma
0.050 Biomarker disease BEFREE In this study, we investigated the effect of long-term exposure to 5% low oxygen atmosphere on human chondrosarcoma HCS-2/8 cells. 28865129 2018
CUI: C0008479
Disease: Chondrosarcoma
Chondrosarcoma
0.050 GeneticVariation disease BEFREE Meclozine also ameliorated abnormally suppressed proliferation of human chondrosarcoma (HCS-2/8) cells that were infected with lentivirus expressing constitutively active mutants of FGFR3-K650E causing thanatophoric dysplasia, FGFR3-K650M causing SADDAN, and FGFR3-G380R causing ACH. 24324705 2013
CUI: C0008479
Disease: Chondrosarcoma
Chondrosarcoma
0.050 Biomarker disease BEFREE New clonal-cell lines HCS-TG C3 and E2 derived from human chondrosarcoma are morphologically chondrocytic in serial monolayer cultures and express chondrocytic phenotypes. 15118855 2004
CUI: C0008479
Disease: Chondrosarcoma
Chondrosarcoma
0.050 Biomarker disease BEFREE Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I. 11458815 2001
CUI: C0008479
Disease: Chondrosarcoma
Chondrosarcoma
0.050 Biomarker disease BEFREE HCS-2/8 is a stable human chondrosarcoma cell line with many chondrocytic characteristics and has the capacity to form chondrosarcomas in nude mice. 8200849 1994
CUI: C0011644
Disease: Scleroderma
Scleroderma
0.030 Biomarker disease BEFREE Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included. 31233287 2019
CUI: C0011644
Disease: Scleroderma
Scleroderma
0.030 Biomarker disease BEFREE A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry. 31535689 2019
CUI: C0036421
Disease: Systemic Scleroderma
Systemic Scleroderma
0.030 Biomarker disease BEFREE Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included. 31233287 2019
CUI: C0036421
Disease: Systemic Scleroderma
Systemic Scleroderma
0.030 Biomarker disease BEFREE A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry. 31535689 2019
CUI: C0206062
Disease: Lung Diseases, Interstitial
Lung Diseases, Interstitial
0.030 Biomarker group BEFREE In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year. 31233287 2019
CUI: C0206062
Disease: Lung Diseases, Interstitial
Lung Diseases, Interstitial
0.030 Biomarker group BEFREE Our aim was to determine whether use of CYC or MMF was associated with an improved ILD course in patients with normal or mildly impaired lung function. 31535689 2019
CUI: C0011644
Disease: Scleroderma
Scleroderma
0.030 Biomarker disease BEFREE RTX is a safe and effective alternative to CYC in the primary therapy of skin and lung manifestations of scleroderma. 30053212 2018
CUI: C0036421
Disease: Systemic Scleroderma
Systemic Scleroderma
0.030 Biomarker disease BEFREE RTX is a safe and effective alternative to CYC in the primary therapy of skin and lung manifestations of scleroderma. 30053212 2018